CoChat

The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients

Open access

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

Impairment of dendritic cells (DC), the most effective activators of anticancer immune responses, is one mechanism for defective antitumor immunity, but the causes of DC impairment are incompletely understood. We evaluated the association of impaired DC differentiation with angiogenesis-associated molecules D-dimer, vascular endothelial growth factor (VEGF), urokinase plasminogen activator (uPA), and plasminogen activator inhibitor (PAI-1) in peripheral blood from 41 patients with lung, breast, and colorectal carcinoma. Subsequently, we studied the effect of administration of the anti-VEGF antibody (bevacizumab) on DC maturation and function in vivo. Compared with healthy volunteers, cancer patients had a bias toward the immunoregulatory DC2, had deficits in DC maturation after overnight in vitro culture, and had a significant increase in immature myeloid cell progenitors of DC (0.50 +/- 0.31% vs. 0.32 +/- 0.16% of peripheral blood mononuclear cells, respectively, P = 0.011). A positive correlation was found between the percentage of DC2 and PAI-1 (R = 0.50) and between immature myeloid cells and VEGF (R = 0.52). Bevacizumab administration to cancer patients was associated with a decrease in the accumulation of immature progenitor cells (0.39 +/- 0.30% vs. 0.27 +/- 0.24%, P = 0.012) and induced a modest increase in the DC population in peripheral blood (0.47 +/- 0.23% vs. 0.53 +/- 0.30%). Moreover, anti-VEGF antibody treatment enhanced allo-stimulatory capacity of DC and T cell proliferation against recall antigens. These data suggest that DC differentiation is negatively associated with VEGF levels and may be one explanation for impaired anticancer immunity, especially in patients with advanced malignancies.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00262-007-0441-x

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 35 references

Cited by

Items 201–300 of 324

Metadata

Authors
Osada, T., Chong, G., Tansik, R., Hong, T., Spector, N., Kumar, R., Hurwitz, H. I., Dev, I., Nixon, A. B., Lyerly, H. K., Clay, T., & Morse, M. A.
Affiliations
  • Duke Medical Center (US)
  • GlaxoSmithKline (United Kingdom) (GB)
  • Hartford Hospital (US)
Corresponding author
Morse, Michael A.
Venue
Cancer Immunology Immunotherapy
Published
2008-01-10
Volume
57
Issue
8
Pages
1115-1124
ISSN
  • 0340-7004 (ISSN-L)
  • 1432-0851
OpenAlex
W2067969350
Cited by
311
References
35
Citations by year
2026: 7 · 2025: 11 · 2024: 15 · 2023: 22 · 2022: 18 · 2021: 30 · 2020: 26 · 2019: 16 · 2018: 24 · 2017: 21 · 2016: 19 · 2015: 12 · 2014: 13 · 2013: 14 · 2012: 10
FWCI
7.26
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Cancer Immunology Immunotherapy (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • GlaxoSmithKline
  • National Cancer Institute (K24CA113755, P01CA078673, 5 P01 CA78673.)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords
anti-VEGF therapy, bevacizumab, dendritic cells, immature myeloid cells, DC2, dendritic cell maturation, vascular endothelial growth factor, angiogenesis, plasminogen activator inhibitor-1, urokinase, D-dimer, antitumor immunity, lung cancer, breast cancer, colorectal cancer, T cell proliferation
MeSH terms
Bevacizumab, Antibodies, Monoclonal, Breast Neoplasms, Cell Differentiation, Cells, Cultured, Dendritic Cells, Fibrin Fibrinogen Degradation Products, Humans, Immunotherapy, Lung Neoplasms, Neovascularization, Pathologic, Pilot Projects, T-Lymphocytes, Urokinase-Type Plasminogen Activator, Colorectal Neoplasms, Plasminogen Activator Inhibitor 1, Angiogenesis Inhibitors, Myeloid Progenitor Cells, Vascular Endothelial Growth Factor A, Cell Proliferation, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.